151 related articles for article (PubMed ID: 6553515)
1. Thymosin alpha 1 restores NK-cell activity and prevents tumor progression in mice immunosuppressed by cytostatics or X-rays.
Umeda Y; Sakamoto A; Nakamura J; Ishitsuka H; Yagi Y
Cancer Immunol Immunother; 1983; 15(2):78-83. PubMed ID: 6553515
[TBL] [Abstract][Full Text] [Related]
2. Protective activity of thymosin alpha 1 against tumor progression in immunosuppressed mice.
Ishitsuka H; Umeda Y; Sakamoto A; Yagi Y
Adv Exp Med Biol; 1983; 166():89-100. PubMed ID: 6650286
[TBL] [Abstract][Full Text] [Related]
3. Immunomodulating activity of thymosin fraction 5 and thymosin alpha 1 in immunosuppressed mice.
Ohta Y; Sueki K; Yoneyama Y; Tezuka E; Yagi Y
Cancer Immunol Immunother; 1983; 15(2):108-13. PubMed ID: 6553511
[TBL] [Abstract][Full Text] [Related]
4. Thymosin alpha 1 exerts protective effect against the 5-FU induced bone marrow toxicity.
Ohta Y; Tezuka E; Tamura S; Yagi Y
Int J Immunopharmacol; 1985; 7(5):761-8. PubMed ID: 4044100
[TBL] [Abstract][Full Text] [Related]
5. Resistance to L1210 mouse leukemia cells in moderately protein-malnourished BALB/c mice treated in vivo with thymosin fraction V.
Petro TM; Watson RR
Cancer Res; 1982 Jun; 42(6):2139-45. PubMed ID: 6804089
[TBL] [Abstract][Full Text] [Related]
6. Mechanism of antitumor action of pyrimidinones in the treatment of B16 melanoma and P388 leukemia.
Li LH; Wallace TL; Richard KA; Tracey DE
Cancer Res; 1985 Feb; 45(2):532-8. PubMed ID: 3967227
[TBL] [Abstract][Full Text] [Related]
7. Increase of mouse resistance to Candida albicans infection by thymosin alpha 1.
Bistoni F; Marconi P; Frati L; Bonmassar E; Garaci E
Infect Immun; 1982 May; 36(2):609-14. PubMed ID: 7085074
[TBL] [Abstract][Full Text] [Related]
8. Modulation of natural killer activity by thymosin alpha 1 and interferon.
Favalli C; Jezzi T; Mastino A; Rinaldi-Garaci C; Riccardi C; Garaci E
Cancer Immunol Immunother; 1985; 20(3):189-92. PubMed ID: 3851698
[TBL] [Abstract][Full Text] [Related]
9. Anti-tumor effect of combined treatment with thymosin alpha 1 and interleukin-2 after 5-fluorouracil in liver metastases from colorectal cancer in rats.
Rasi G; Silecchia G; Sinibaldi-Vallebona P; Spaziani E; Pierimarchi P; Sivilia M; Tremiterra S; Garaci E
Int J Cancer; 1994 Jun; 57(5):701-5. PubMed ID: 8194879
[TBL] [Abstract][Full Text] [Related]
10. Synergistic effect of thymosin alpha 1 and alpha beta-interferon on NK activity in tumor-bearing mice.
Favalli C; Mastino A; Jezzi T; Grelli S; Goldstein AL; Garaci E
Int J Immunopharmacol; 1989; 11(5):443-50. PubMed ID: 2807622
[TBL] [Abstract][Full Text] [Related]
11. Modulation of endogenous prostaglandins by thymosin-alpha 1 in lymphocytes.
Rinaldi-Garaci C; Garaci E; Del Gobbo V; Favalli C; Jezzi T; Goldstein AL
Cell Immunol; 1983 Aug; 80(1):57-65. PubMed ID: 6575878
[TBL] [Abstract][Full Text] [Related]
12. Interaction between thymosin, testosterone and estradiol on natural killer cell activity in mice.
Deschaux P; Paucod JC; Ardail D
Tohoku J Exp Med; 1982 Apr; 136(4):367-72. PubMed ID: 7101272
[TBL] [Abstract][Full Text] [Related]
13. Tuftsin: an immunomodulating peptide hormone and its clinical potential as a natural biological response modifier.
Nishioka K; Amoscato AA; Babcock GF; Banks RA; Phillips JH
Cancer Invest; 1984; 2(1):39-49. PubMed ID: 6322938
[No Abstract] [Full Text] [Related]
14. Combination treatment using thymosin alpha 1 and interferon after cyclophosphamide is able to cure Lewis lung carcinoma in mice.
Garaci E; Mastino A; Pica F; Favalli C
Cancer Immunol Immunother; 1990; 32(3):154-60. PubMed ID: 2126987
[TBL] [Abstract][Full Text] [Related]
15. [Studies on the possible causes of decreasing NK cell activity in tumor-bearing mice. II. Serum and peritoneal exudate from ascitic tumor-bearing mice suppress NK cell activity].
Fu JY
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1989 Dec; 11(6):446-8. PubMed ID: 2534583
[TBL] [Abstract][Full Text] [Related]
16. Thymosin alpha one restores murine T-cell-mediated responses inhibited by in vivo cocaine administration.
Di Francesco P; Pica F; Marini S; Favalli C; Garaci E
Int J Immunopharmacol; 1992 Jan; 14(1):1-9. PubMed ID: 1582729
[TBL] [Abstract][Full Text] [Related]
17. Induction of tumor-specific T lymphocyte responses in vivo by prothymosin alpha.
Baxevanis CN; Gritzapis AD; Spanakos G; Tsitsilonis OE; Papamichail M
Cancer Immunol Immunother; 1995 Jun; 40(6):410-8. PubMed ID: 7543022
[TBL] [Abstract][Full Text] [Related]
18. [Studies on the possible causes of decreasing NK cell activity in tumor-bearing mice. I. The number of NK cells in the spleens of tumor-bearing mice is higher than that in normal mice].
Fu JY
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1989 Dec; 11(6):421-4. PubMed ID: 2534577
[TBL] [Abstract][Full Text] [Related]
19. Involvement of cytotoxic T-lymphocytes in the antitumor activity of spergualin against L1210 cells.
Umezawa H; Nishikawa K; Shibasaki C; Takahashi K; Nakamura T; Takeuchi T
Cancer Res; 1987 Jun; 47(12):3062-5. PubMed ID: 3495325
[TBL] [Abstract][Full Text] [Related]
20. Antitumor effect of thymosin alpha 1/interleukin-2 or thymosin alpha 1/interferon alpha,beta following cyclophosphamide in mice injected with highly metastatic Friend erythroleukemia cells.
Garaci E; Pica F; Mastino A; Palamara AT; Belardelli F; Favalli C
J Immunother Emphasis Tumor Immunol; 1993 Jan; 13(1):7-17. PubMed ID: 8435433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
